The study assessed 27 protocol-compliant patients, comparing the dual GLP-1/glucagon receptor agonist against a placebo. Beyond stage-level improvements, the quantitative analysis revealed a -41.0% relative change in steatosis-corrected qFibrosis scores for the treatment group, starkly contrasting with a +9.5% increase among those receiving the placebo. These findings corroborate earlier results from the trial, which indicated that the drug effectively promotes weight loss and glycemic control while resolving inflammation associated with metabolic dysfunction-associated steatohepatitis.

Seulki Lee, CEO of D&D Pharmatech, noted that the AI-driven insights provided an essential layer of objectivity to the trial, strengthening confidence in the drug’s ability to reverse liver scarring. Dr. Mazen Noureddin, the trial’s coordinating investigator, emphasized that the sensitivity of AI-powered pathology tools is becoming a critical component in evaluating treatment responses. By moving beyond traditional categorical scoring, which often struggles to capture the heterogeneity of MASH, this approach offers a more precise metric for drug development. The companies plan to present further data from this analysis at upcoming scientific conferences.